Focused On-demand Library for Solute carrier family 2, facilitated glucose transporter member 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P11169

UPID:

GTR3_HUMAN

Alternative names:

Glucose transporter type 3, brain

Alternative UPACC:

P11169; B2R606; D3DUU6; Q6I9U2; Q9UG15

Background:

Solute carrier family 2, facilitated glucose transporter member 3, also known as Glucose transporter type 3, brain, is a pivotal protein in glucose metabolism. It facilitates the transport of glucose and other monosaccharides across cell membranes, playing a crucial role in energy supply within the brain. Unlike other glucose transporters, it does not support fructose transport, highlighting its specificity and importance in glucose homeostasis.

Therapeutic significance:

Understanding the role of Solute carrier family 2, facilitated glucose transporter member 3 could open doors to potential therapeutic strategies. Its critical function in glucose transport and metabolism positions it as a key target for addressing metabolic disorders and enhancing brain energy supply.